{
    "clinical_study": {
        "@rank": "77532", 
        "arm_group": {
            "arm_group_label": "vaccine", 
            "arm_group_type": "Experimental", 
            "description": "This is a dose-escalation study of GPI-0100.\nPatients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.\nCohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.\nPatients are followed every 3 months."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.\n      Biological therapies use different ways to stimulate the immune system and stop cancer cells\n      from growing. Combining vaccine therapy with biological therapy may kill more tumor cells.\n\n      PURPOSE: Phase I trial to study the effectiveness in combining vaccine therapy and\n      biological therapy in treating patients who have relapsed prostate cancer."
        }, 
        "brief_title": "Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the optimal (in terms of antibody response) and safe dose range of\n           glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 in patients\n           with biochemically relapsed prostate cancer.\n\n        -  Assess post-immunization changes in prostate-specific antigen levels and other\n           objective parameters of disease in these patients.\n\n      OUTLINE: This is a dose-escalation study of GPI-0100.\n\n      Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100\n      subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or\n      disease progression.\n\n      Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on\n      antibody response, is reached.\n\n      Patients are followed every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed prostate cancer\n\n          -  Biochemically progressive disease after primary surgery or radiotherapy with or\n             without neoadjuvant androgen ablation\n\n               -  Greater than 50% increase in PSA level above baseline value of 1.0 ng/mL\n                  post-prostatectomy or 2.0 ng/mL post-radiotherapy, based on 3 successive\n                  determinations taken at 2-week intervals\n\n          -  Patients with prior intermittent hormonal therapy and non-castrate levels of\n             testosterone are eligible\n\n          -  Evaluable disease\n\n          -  No radiographic evidence of metastasis\n\n          -  No active CNS or epidural tumor\n\n          -  No soft tissue and/or bone disease\n\n          -  No androgen-independence with no evidence of radiographic disease\n\n          -  May not be symptomatic or anticipated to develop symptoms within 6 months of study\n             entry\n\n          -  Concurrent registration to protocol MSKCC-90-040 required\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  At least 6 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 2.0 mg/dL OR\n\n          -  SGOT less than 3 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL OR\n\n          -  Creatinine clearance at least 40 mL/min\n\n        Cardiovascular:\n\n          -  No clinically significant cardiac disease (New York Heart Association class III or\n             IV)\n\n        Pulmonary:\n\n          -  No severe debilitating pulmonary disease\n\n        Other:\n\n          -  No other prior malignancy within the past 5 years except nonmelanoma skin cancer\n\n          -  No positive stool guaiac except hemorrhoids or history of documented\n             radiation-induced proctitis\n\n          -  No narcotic-dependent pain\n\n          -  No infection requiring antibiotics\n\n          -  No requirement for immunosuppressive therapy\n\n          -  No allergy to seafood\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n          -  At least 2 weeks since change in hormonal therapy (except to maintain castrate levels\n             of testosterone), including prednisone or dexamethasone\n\n          -  At least 8 weeks since prior suramin and/or documented plasma concentration\n\n          -  of suramin is less than 50 micrograms/mL (replacement hydrocortisone allowed)\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy to only measurable lesion\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  No concurrent surgery of only measurable lesion\n\n        Other:\n\n          -  Recovered from prior therapy\n\n          -  No other concurrent oncolytic agents\n\n          -  No concurrent immunosuppressive therapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00016146", 
            "org_study_id": "99-062", 
            "secondary_id": [
                "P30CA008748", 
                "MSKCC-99062", 
                "NCI-G01-1941"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "vaccine", 
                "intervention_name": "GPI-0100", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "vaccine", 
                "intervention_name": "MUC-2-Globo H-KLH conjugate vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adjuvants, Immunologic"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "recurrent prostate cancer", 
        "lastchanged_date": "March 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-99062"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates: A Dose-Escalating Trial Studying The Immunogenicity And Safety Of The Immunological Adjuvant GPI-0100", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Susan Slovin, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00016146"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "immune function", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2000", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}